A Safety and Tolerability Study of Jaktinib
NCT05279001
Recruiting
This research study is studying a drug called Jaktinib as a possible treatment for Myelofibrosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Site 01, Canton, Ohio
Conditions: Myelofibrosis
Register for Updates
Gentamicin Bladder Instillation on CAUTI
NCT06332040
Recruiting
Urinary tract infections in catheterized patients is an unacceptable complication and has been termed a 'never event' by the Center for Medicare \& Medicaid Services (CMS); however there is not consensus among clinicians on how to best prevent CAUTIs. We propose a prospective randomized controlled trial to test the efficacy of prophylactic gentamicin bladder irrigation in elimination of CAUTIs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: St. Jpseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: Catheter Infection
Register for Updates
Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances
NCT03154697
Recruiting
This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.
Gender:
ALL
Ages:
Between 3 years and 65 years
Trial Updated:
03/19/2024
Locations: Vanda Pharmaceuticals, Washington, District of Columbia
Conditions: Sleep Disturbances in Smith-Magenis Syndrome
Register for Updates
Microbiotic Product to Promote Microbiome Health and Improve Chemotherapy Delivery
NCT05296681
Recruiting
This phase II trial tests whether NBT-NM108 works in reducing chemotherapy-induced diarrhea in patients with colon cancer that has spread to other places in the body (metastatic). Irinotecan is one of the most used medicine for colon cancer, but it leads to diarrhea in most patients receiving it and among some of them, severe diarrhea can occur. NBT-NM108 is a high dietary fiber formula that is developed based on research findings that have shown that high fiber diets can help maintain healthy b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Robert Wood Johnson University Hospital, Hamilton, Hamilton, New Jersey +9 locations
Conditions: Metastatic Colon Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8
Register for Updates
Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)
NCT06334419
Recruiting
This is a single dose, placebo-controlled study. Male subjects aged 18 to 40 years (inclusive) with a diagnosis of FXS. Eligible subjects may enroll in this study comprised of two in home and two in clinic visits each 14 days apart, for a total of four visits. Subjects will be given single dose gaboxadol (10 mg) or matched placebo at each of these visits to take orally. Thus, all enrolled subjects will receive placebo at home and in clinic and receive gaboxadol at home and in clinic in a blinded... Read More
Gender:
MALE
Ages:
Between 18 years and 40 years
Trial Updated:
03/19/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Fragile X Syndrome
Register for Updates
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
NCT03803553
Recruiting
This research study is comparing two standard of care treatment options based on blood test results for participants who have metastatic colon cancer. The names of the potential treatments involved in this study are: * Active surveillance * FOLFIRI treatment * Nivolumab treatment * Encorafenib/Binimetinib/Cetuximab treatment * Trastuzumab + Pertuzumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Metastatic Colon Cancer, Stage III Colon Cancer
Register for Updates
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05361707
Recruiting
This is a multicenter, open-label study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon in treating sleep disturbances in pediatric and adult participants with ASD.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
03/19/2024
Locations: Vanda Investigational Site, San Jose, California +4 locations
Conditions: Autism Spectrum Disorder, Sleep Disorder, Neurological Disorder, Sleep Disturbance
Register for Updates
Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy
NCT03813056
Recruiting
Recently, published literature has reported that performing a descemetorhexis in combination with topical Rho kinase (ROCK) inhibitor therapy was successful in clearing edematous corneas in patients with Fuchs Endothelial Corneal Dystrophy. Ripasudil hydrochloride hydrate( Glanatec ophthalmic solution 0.4%), a potent ROCK inhibitor, has been approved in Japan since 2014 for ocular use in the treatment of glaucoma. Ripasudil acts as an IOP-lowering drug by affecting aqueous outflow through the t... Read More
Gender:
ALL
Ages:
Between 30 years and 99 years
Trial Updated:
03/19/2024
Locations: Devers Eye Institute, Portland, Oregon
Conditions: Fuchs Endothelial Dystrophy
Register for Updates
Comparing Insomnia Care As Usual to Digital Augmentation (CICADA)
NCT05490550
Recruiting
The purpose of this pragmatic non-inferiority randomized clinical trial is to evaluate whether Cognitive Behavioral Treatment of Insomnia (CBTI) delivered through a clinical decision support digital platform is non-inferior to insomnia care delivered as usual at three military treatment facilities for treatment of insomnia, symptoms of depression and anxiety, and treatment satisfaction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Madigan Army Medical Center, Lakewood, Washington
Conditions: Chronic Insomnia
Register for Updates
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
NCT04028492
Recruiting
To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/19/2024
Locations: Vanda Investigational Site, Birmingham, Alabama +35 locations
Conditions: Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
Register for Updates
Effect of Beet-root Juice and PBM Treatments on Muscle Fatigue
NCT05596474
Recruiting
The goal of this randomized counterbalanced repeated measures study is to test beet-root juice supplementation and red light therapy augment forearm muscle endurance in apparently healthy older adults over 65 years of age. The main questions seek to answer the following question: Does beet-root juice supplementation improve forearm muscle endurance compared to a placebo supplement? Does red light therapy improve forearm muscle endurance compared to a sham light exposure? Does beet-root juice... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/19/2024
Locations: Wake Forest Univesity, Winston-Salem, North Carolina
Conditions: Health Care Utilization, Healthy Aging
Register for Updates
Recovery of Bladder and Sexual Function After Human Spinal Cord Injury
NCT04193709
Recruiting
This study will incorporate critical cross viscero-visceral intersystem interactions to 1) investigate in a controlled laboratory setting and then with mobile at-home monitoring the extent, severity, and frequency of occurrence of autonomic dysreflexia with respect to daily bladder and bowel function, in conjunction with identifying potential underlying mechanisms by examining urinary biomarkers for several specific vasoactive hormones, and 2) to regulate cardiovascular function therapeutically... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/19/2024
Locations: University of Louisville, Louisville, Kentucky
Conditions: Urinary Bladder, Neurogenic, Blood Pressure, Autonomic Dysreflexia, Bowel Incontinence
Register for Updates